{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:36:11Z","timestamp":1783427771601,"version":"3.54.6"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["ICMx"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Clogging is characterized by a progressive impairment of transmembrane patency in renal replacement devices and occurs due to obstruction of pores by unknown molecules. If citrate-based anti-coagulation is used, clogging can manifest as a metabolic alkalosis accompanied by hypernatremia and hypercalcemia, primarily a consequence of Na<jats:sub>3<\/jats:sub>Citrate infusion. An increased incidence of clogging has been observed during the COVID-19 pandemic. However, precise factors contributing to the formation remain uncertain. This investigation aimed to analyze its incidence and assessed time-varying trajectories of associated factors in critically ill patients on continuous renal replacement therapy (CRRT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective, single-center data analysis, we evaluated COVID-19 patients undergoing CRRT and admitted to critical care between March 2020 and December 2021. We assessed the proportional incidence of clogging surrogates in the overall population and subgroups based on the specific CRRT devices employed at our institution, including multiFiltrate (Fresenius Medical Care) and Prismaflex System (Baxter). Moderate and severe clogging were defined as Na\u2009&gt;\u2009145 or\u2009\u2265\u2009150\u00a0mmol\/l and HCO<jats:sub>3<\/jats:sub><jats:sup>\u2212<\/jats:sup>\u2009&gt;\u200928.0 or\u2009\u2265\u200930\u00a0mmol\/l, respectively, with a total albumin-corrected calcium\u2009&gt;\u20092.54\u00a0mmol\/l. A mixed effect model was introduced to investigate factors associated with development of clogging.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty-three patients with 240 CRRT runs were analyzed. Moderate and severe clogging occurred in 15% (8\/53) and 19% (10\/53) of patients, respectively. Twenty-seven percent (37\/136) of CRRTs conducted with a multiFiltrate device met the criteria for clogging, whereas no clogging could be observed in patients dialyzed with the Prismaflex System. Occurrence of clogging was associated with elevated triglyceride plasma levels at filter start (<jats:italic>p<\/jats:italic>\u2009=\u20090.013), amount of enteral nutrition (<jats:italic>p<\/jats:italic>\u2009=\u20090.002) and an increasing white blood cell count over time (<jats:italic>p<\/jats:italic>\u2009=\u20090.002).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Clogging seems to be a frequently observed phenomenon in critically ill COVID-19 patients. The presence of hypertriglyceridemia, combined with systemic inflammation, may facilitate the development of an impermeable secondary membrane within filters, thereby contributing to compromised membrane patency.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s40635-023-00581-9","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T13:02:17Z","timestamp":1703163737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Metabolic disturbances potentially attributable to clogging during continuous renal replacement therapy"],"prefix":"10.1186","volume":"11","author":[{"given":"Mattia M.","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larina","family":"Caspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur","family":"Sazpinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Hofmaenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Erlebach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rea","family":"Andermatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph C.","family":"Ganter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reto A.","family":"Schuepbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro D.","family":"Wendel-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8231-0461","authenticated-orcid":false,"given":"Sascha","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"581_CR1","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41581-020-00356-5","volume":"16","author":"MK Nadim","year":"2020","unstructured":"Nadim MK, Forni LG, Mehta RL, Connor MJ Jr, Liu KD, Ostermann M, Rimmele T, Zarbock A, Bell S, Bihorac A, Cantaluppi V, Hoste E, Husain-Syed F, Germain MJ, Goldstein SL, Gupta S, Joannidis M, Kashani K, Koyner JL, Legrand M, Lumlertgul N, Mohan S, Pannu N, Peng Z, Perez-Fernandez XL, Pickkers P, Prowle J, Reis T, Srisawat N, Tolwani A, Vijayan A, Villa G, Yang L, Ronco C, Kellum JA (2020) COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nat Rev Nephrol 16:747\u2013764","journal-title":"Nat Rev Nephrol"},{"key":"581_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.705908","volume":"9","author":"T Sabaghian","year":"2022","unstructured":"Sabaghian T, Kharazmi AB, Ansari A, Omidi F, Kazemi SN, Hajikhani B, Vaziri-Harami R, Tajbakhsh A, Omidi S, Haddadi S, Shahidi Bonjar AH, Nasiri MJ, Mirsaeidi M (2022) COVID-19 and acute kidney injury: a systematic review. Front Med (Lausanne) 9:705908","journal-title":"Front Med (Lausanne)"},{"key":"581_CR3","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1007\/s00134-015-4099-0","volume":"41","author":"M Bai","year":"2015","unstructured":"Bai M, Zhou M, He L, Ma F, Li Y, Yu Y, Wang P, Li L, Jing R, Zhao L, Sun S (2015) Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs. Intensive Care Med 41:2098\u20132110","journal-title":"Intensive Care Med"},{"key":"581_CR4","doi-asserted-by":"crossref","unstructured":"Li R, Gao X, Zhou T, Li Y, Wang J, Zhang P (2022) Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis of randomized controlled trials. Ther Apher Dial.","DOI":"10.1111\/1744-9987.13850"},{"key":"581_CR5","unstructured":"KDIGO (2012) Kidney Disease improving Glonal outcomes\u2014clinical practice guideline for acute kidney injury. KI Supplements 2"},{"key":"581_CR6","doi-asserted-by":"publisher","first-page":"c5","DOI":"10.1159\/000112043","volume":"108","author":"A Kazory","year":"2008","unstructured":"Kazory A, Clapp WL, Ejaz AA, Ross EA (2008) Shortened hemofilter survival time due to lipid infusion in continuous renal replacement therapy. Nephron Clin Pract 108:c5-9","journal-title":"Nephron Clin Pract"},{"key":"581_CR7","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1053\/j.ajkd.2014.01.417","volume":"63","author":"E Bassi","year":"2014","unstructured":"Bassi E, Ferreira CB, Macedo E, Malbouisson LM (2014) Recurrent clotting of dialysis filter associated with hypertriglyceridemia induced by propofol. Am J Kidney Dis 63:860\u2013861","journal-title":"Am J Kidney Dis"},{"key":"581_CR8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4103\/ijn.IJN_201_17","volume":"28","author":"DC McLaughlin","year":"2018","unstructured":"McLaughlin DC, Fang DC, Nolot BA, Guru PK (2018) Hypertriglyceridemia causing continuous renal replacement therapy dysfunction in a patient with end-stage liver disease. Indian J Nephrol 28:303\u2013306","journal-title":"Indian J Nephrol"},{"key":"581_CR9","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1097\/ALN.0000000000002058","volume":"128","author":"R Diaz Milian","year":"2018","unstructured":"Diaz Milian R, Diaz Galdo R, Castresana MR (2018) Images in anesthesiology: a clogged dialysis filter caused by severe acutely induced hypertriglyceridemia. Anesthesiology 128:1237","journal-title":"Anesthesiology"},{"key":"581_CR10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.xkme.2021.02.011","volume":"3","author":"SR Kanduri","year":"2021","unstructured":"Kanduri SR, LeDoux JR, Kovvuru K, Wu Q, Velez JC (2021) Multiple myeloma, hyperviscosity, hemodialysis filter clogging, and antigen excess artifact: a case report. Kidney Med 3:649\u2013652","journal-title":"Kidney Med"},{"key":"581_CR11","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.34067\/KID.0004322020","volume":"1","author":"Y Wen","year":"2020","unstructured":"Wen Y, LeDoux JR, Mohamed M, Ramanand A, Scharwath K, Mundy D, Lukitsch I, Velez JCQ (2020) Dialysis filter life, anticoagulation, and inflammation in COVID-19 and acute kidney injury. Kidney360 1:1426\u20131431","journal-title":"Kidney360"},{"key":"581_CR12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s13054-017-1880-1","volume":"21","author":"AG Schneider","year":"2017","unstructured":"Schneider AG, Journois D, Rimmele T (2017) Complications of regional citrate anticoagulation: accumulation or overload? Crit Care 21:281","journal-title":"Crit Care"},{"key":"581_CR13","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jcrc.2021.10.010","volume":"67","author":"D Khadzhynov","year":"2022","unstructured":"Khadzhynov D, von dem Berge U, Muench F, Karaivanov S, Koerner R, Kruse JM, Zickler D, Budde K, Eckardt KU, Lehner LJ (2022) Efficacy and complications of regional citrate anticoagulation during continuous renal replacement therapy in critically ill patients with COVID-19. J Crit Care 67:126\u2013131","journal-title":"J Crit Care"},{"key":"581_CR14","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3390\/membranes12100932","volume":"12","author":"AM Zawada","year":"2022","unstructured":"Zawada AM, Lang T, Ottillinger B, Kircelli F, Stauss-Grabo M, Kennedy JP (2022) Impact of hydrophilic modification of synthetic dialysis membranes on hemocompatibility and performance. Membranes (Basel) 12:932","journal-title":"Membranes (Basel)"},{"key":"581_CR15","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/ki.1986.202","volume":"30","author":"A Rockel","year":"1986","unstructured":"Rockel A, Hertel J, Fiegel P, Abdelhamid S, Panitz N, Walb D (1986) Permeability and secondary membrane formation of a high flux polysulfone hemofilter. Kidney Int 30:429\u2013432","journal-title":"Kidney Int"},{"key":"581_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s42765-023-00277-5","author":"H Ji","year":"2023","unstructured":"Ji H, Li Y, Su B, Zhao W, Kizhakkedathu JN, Zhao C (2023) Advances in enhancing hemocompatibility of hemodialysis hollow-fiber membranes. Adv Fiber Mater. https:\/\/doi.org\/10.1007\/s42765-023-00277-5","journal-title":"Adv Fiber Mater"},{"key":"581_CR17","doi-asserted-by":"publisher","first-page":"844","DOI":"10.3390\/biomedicines10040844","volume":"10","author":"M Bonomini","year":"2022","unstructured":"Bonomini M, Piscitani L, Di Liberato L, Sirolli V (2022) Biocompatibility of surface-modified membranes for chronic hemodialysis therapy. Biomedicines 10:844","journal-title":"Biomedicines"},{"key":"581_CR18","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jemermed.2014.07.040","volume":"47","author":"B Rodriguez","year":"2014","unstructured":"Rodriguez B, Wilhelm A, Kokko KE (2014) Lipid emulsion use precluding renal replacement therapy. J Emerg Med 47:635\u2013637","journal-title":"J Emerg Med"},{"key":"581_CR19","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1007\/s00467-015-3305-1","volume":"31","author":"A Kakajiwala","year":"2016","unstructured":"Kakajiwala A, Chiotos K, Brothers J, Lederman A, Amaral S (2016) What is this chocolate milk in my circuit? A cause of acute clotting of a continuous renal replacement circuit: questions. Pediatr Nephrol 31:2249\u20132251","journal-title":"Pediatr Nephrol"},{"key":"581_CR20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.34067\/KID.0000092019","volume":"1","author":"M Whitlow","year":"2020","unstructured":"Whitlow M, Rajasekaran A, Rizk D (2020) Unusual cause for continuous renal replacement therapy filter clotting. Kidney360 1:225\u2013226","journal-title":"Kidney360"}],"container-title":["Intensive Care Medicine Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40635-023-00581-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40635-023-00581-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40635-023-00581-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T16:20:02Z","timestamp":1730910002000},"score":1,"resource":{"primary":{"URL":"https:\/\/icm-experimental.springeropen.com\/articles\/10.1186\/s40635-023-00581-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["581"],"URL":"https:\/\/doi.org\/10.1186\/s40635-023-00581-9","relation":{},"ISSN":["2197-425X"],"issn-type":[{"value":"2197-425X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]},"assertion":[{"value":"10 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received approval from the Ethics Commission Board of the Canton of Zurich (BASEC-Nr. 2022-00285). All patients, who did not refuse the further use of their medical-related data for research purposes orally or by writing were assessed for eligibility.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors have financial nor non-financial competing interest in association with this study.SD is part of the editorial board of Intensive Care Medicine Experimental.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}